The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Open accessAbstract
BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elevated RAS-mitogen-activated protein kinase (MAPK) signaling. METHODS: We conducted a phase 1 trial of selumetinib (AZD6244 or ARRY-142886), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maximum tolerated dose and to evaluate plasma pharmacokinetics. Selumetinib was administered twice daily at a dose of 20 to 30 mg per square meter of body-surface area on a continuous dosing schedule (in 28-day cycles). We also tested selumetinib using a mouse model of neurofibromatosis type 1-related neurofibroma. Response to treatment (i.e., an increase or decrease from baseline in the volume of plexiform neurofibromas) was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma. RESULTS: A total of 24 children (median age, 10.9 years; range, 3.0 to 18.5) with a median tumor volume of 1205 ml (range, 29 to 8744) received selumetinib. Patients were able to receive selumetinib on a long-term basis; the median number of cycles was 30 (range, 6 to 56). The maximum tolerated dose was 25 mg per square meter (approximately 60% of the recommended adult dose). The most common toxic effects associated with selumetinib included acneiform rash, gastrointestinal effects, and asymptomatic creatine kinase elevation. The results of pharmacokinetic evaluations of selumetinib among the children in this trial were similar to those published for adults. Treatment with selumetinib resulted in confirmed partial responses (tumor volume decreases from baseline of ≥20%) in 17 of the 24 children (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%). Disease progression (tumor volume increase from baseline of ≥20%) has not been observed to date. Anecdotal evidence of decreases in tumor-related pain, disfigurement, and functional impairment was observed. CONCLUSIONS: Our early-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-term dose-adjusted treatment with selumetinib without having excess toxic effects. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01362803 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Neurofibromatosis type 1: a multidisciplinary approach to care
Hirbe, A. C., & Gutmann, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70063-8 · Cited by 626
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Self-citationKorf, B. R. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990326)89:1<31::aid-ajmg7>3.0.co;2-w · Cited by 390
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow
Yang, F.-C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y., et al. (2008) · Cell · doi:10.1016/j.cell.2008.08.041 · Cited by 364
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
Self-citationNeedle, M. N., Cnaan, A., Dattilo, J., Chatten, J., Phillips, P. C., Shochat, S., Sutton, L. N., Vaughan, S. N., Zackai, E. H., Zhao, H., et al. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70092-1 · Cited by 273
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
Mautner, V.-F., Asuagbor, F. A., Dombi, E., Fünsterer, C., Kluwe, L., Wenzel, R., Widemann, B. C., & Friedman, J. M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-011 · Cited by 260
Self-citationAtypical neurofibromas in neurofibromatosis type 1 are premalignant tumors
Beert, E., Brems, H., Daniëls, B., De Wever, I., Van Calenbergh, F., Schoenaers, J., Debiec‐Rychter, M., Gevaert, O., De Raedt, T., Van Den Bruel, A., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20921 · Cited by 255
Wu, J., Williams, J. P., Rizvi, T. A., Kordich, J. J., Witte, D., Meijer, D., Stemmer-Rachamimov, A. O., Cancelas, J. A., & Ratner, N. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.027 · Cited by 236
Self-citationRobertson, K. A., Nalepa, G., Yang, F.-C., Bowers, D. C., Ho, C. Y., Hutchins, G. D., Croop, J. M., Vik, T. A., Denne, S. C., Parada, L. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70414-x · Cited by 234
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S. G., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 211
NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight
Dombi, E., Solomon, J., Gillespie, A. J., Fox, E., Balis, F. M., Patronas, N., Korf, B. R., Babovic-Vuksanovic, D., Packer, R. J., Belasco, J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000250332.89420.e6 · Cited by 202
Self-citationPlexiform neurofibromas in NF1: Toward biologic-based therapy
Packer, R. J., Gutmann, D. H., Rubenstein, A., Viskochil, D., Zimmerman, R. A., Vezina, G., Small, J., & Korf, B. (2002) · Neurology · doi:10.1212/wnl.58.10.1461 · Cited by 186
Robert, C., Dummer, R., Gutzmer, R., Lorigan, P., Kim, K. B., Nyakas, M., Arance, A., Liszkay, G., Schadendorf, D., Cantarini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70237-7 · Cited by 169
Nguyen, R., Dombi, E., Widemann, B. C., Solomon, J. M., Fünsterer, C., Kluwe, L., Friedman, J. M., & Mautner, V. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-75 · Cited by 167
Self-citationNguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V.-F. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.04.008 · Cited by 159
Weiss, B., Widemann, B. C., Wolters, P. L., Dombi, E., Vinks, A. A. T. M. M., Cantor, A. B., Perentesis, J. P., Schorry, E. K., Ullrich, N. J., Gutmann, D. H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou235 · Cited by 156
Self-citationResponse and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
Lauchle, J., Kim, D. S., Le, D., Akagi, K., Crone, M., Krisman, K., Warner, K., Bonifas, J. M., Li, Q., Coakley, K. M., et al. (2009) · Nature · doi:10.1038/nature08279 · Cited by 154
Recommendations for imaging tumor response in neurofibromatosis clinical trials
Dombi, E., Ardern‐Holmes, S. L., Babovic‐Vuksanovic, D., Barker, F. G., Connor, S. E. J., Evans, D. G., Fisher, M. J., Goutagny, S., Harris, G. J., Jaramillo, D., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000435744.57038.af · Cited by 153
Self-citationWidemann, B. C., Salzer, W. L., Arceci, R. J., Blaney, S. M., Fox, E., End, D. W., Gillespie, A., Whitcomb, P. O., Palumbo, J. S., Pitney, A. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8638 · Cited by 145
Self-citationTherapeutic response in phase I trials of antineoplastic agents.
Estey, E., Hoth, D. F., Simon, R., Marsoni, S., Leyland-Jones, B., & Wittes, R. E. (1986) · PubMed · Cited by 139
Widemann, B. C., Dombi, E., Gillespie, A., Wolters, P. L., Belasco, J. B., Goldman, S., Korf, B. R., Solomon, J. M., Martin, S. C., Salzer, W. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou004 · Cited by 124
Self-citationDermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
Balagula, Y., Huston, K. B., BUSAM, K. J., Lacouture, M. E., Chapman, P. B., & Myskowski, P. L. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9567-3 · Cited by 104
Widemann, B. C., Babovic‐Vuksanovic, D., Dombi, E., Wolters, P. L., Goldman, S., Martin, S. C., Goodwin, A., Goodspeed, W. J., Kieran, M. W., Cohen, B. H., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25041 · Cited by 103
Self-citationConduct of phase I trials in children with cancer.
Smith, M. A., Bernstein, M. L., Bleyer, W. A., Borsi, J. D., Ho, P., Lewis, I. J., Pearson, A., Pein, F. J. L., Pratt, C. B., Reaman, G. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.966 · Cited by 93
Weiss, B., Widemann, B. C., Wolters, P. L., Dombi, E., Vinks, A. A. T. M. M., Cantor, A. B., Korf, B. R., Perentesis, J. P., Gutmann, D. H., Schorry, E. K., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24873 · Cited by 91
Self-citationSolomon, J. M., Warren, K. E., Dombi, E., Patronas, N. J., & Widemann, B. C. (2004) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2004.03.002 · Cited by 90
Self-citationOptimizing biologically targeted clinical trials for neurofibromatosis
Gutmann, D. H., Blakeley, J. O., Korf, B. R., & Packer, R. J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.772979 · Cited by 85
Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas
Kim, A., Gillespie, A., Dombi, E., Goodwin, A., Goodspeed, W. J., Fox, E., Balis, F. M., & Widemann, B. C. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd1326 · Cited by 80
Self-citationJakacki, R. I., Dombi, E., Steinberg, S. M., Goldman, S., Kieran, M. W., Ullrich, N. J., Pollack, I. F., Goodwin, A., Manley, P. E., Fangusaro, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now158 · Cited by 78
Self-citationWu, J., Dombi, E., Jousma, E., Dunn, R. S., Lindquist, D. M., Schnell, B. M., Kim, M., Kim, A., Widemann, B. C., Cripe, T. P., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23015 · Cited by 66
Self-citation
Cited by
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Self-citationSelumetinib in Children with Inoperable Plexiform Neurofibromas
Gross, A. M., Wolters, P. L., Dombi, E., Baldwin, A., Whitcomb, P., Fisher, M. J., Weiss, B., Kim, A., Bornhorst, M., Shah, A. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912735 · Cited by 726
Self-citationFangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Self-citationPediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Sturm, D., Pfister, S. M., & Jones, D. T. W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0242 · Cited by 339
Metadata
- Authors
- Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., Wu, J., Ershler, R., Wolters, P., Therrien, J., Glod, J., Belasco, J. B., Schorry, E., Brofferio, A., Starosta, A. J., Gillespie, A., Doyle, A. L., Ratner, N., & Widemann, B. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-29
- Volume
- 375
- Issue
- 26
- Pages
- 2550-2560
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2567378356
- Cited by
- 682
- References
- 39
- FWCI
- 34.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.